Linezolid Accord

Linezolid, the active ingredient in Linezolid Accord, is a oxazolidinone antibiotic presented as an injection for intravenous use. It treats complicated skin and soft‑tissue infections, community‑acquired and nosocomial pneumonia, and infections caused by methicillin‑resistant Staphylococcus aureus (MRSA) or vancomycin‑resistant Enterococcus (VRE) in adult patients.

GNH USA supplies Linezolid Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable cold‑chain logistics for injectable medicines.

Linezolid is indicated for bacterial infections affecting the skin, lungs and resistant Gram‑positive organisms.

- Complicated skin and soft‑tissue infections: effective against MRSA and other Gram‑positive pathogens, helping resolve infection and promote healing. - Community‑acquired and nosocomial pneumonia: achieves bacterial clearance in lung tissue, improving respiratory function. - Infections caused by methicillin‑resistant Staphylococcus aureus (MRSA): provides targeted activity where other agents may fail. - Infections caused by vancomycin‑resistant Enterococcus (VRE): offers an alternative treatment option for resistant enterococcal infections.

Linezolid may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset occurring in many patients. - Diarrhea: loose stools that may be self‑limiting. - Headache: transient cranial discomfort. - Vomiting: occasional emesis. - Metallic taste: altered taste perception.